CD274 and neoplasm: PD-L1 on both tumor and immune cells were evaluated, Ventana SP142 PD-L1 assay; compared with docetaxel, OS with atezolizumab was improved in patients with ≥1% score (prevalence: 68%) but not in patients with <1% score (HR 0.59 and 1.04; p = 0.005 and 0.87, respectively); ORR with atezolizumab was improved in patients with ≥50% scores (prevalence: 16%), 37.5 vs. 13.0%, but decreased in patients with 5–49% scores (prevalence: 37%), 7.7 vs. 15.6%